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Expression of decay accelerating factor mRNA and complement C3
mRNA in human diseased kidney.
Background. Decay accelerating factor (DAF), a product of mesangial
cells in vitro, is expressed on the surface of cells and is a candidate for the
focal suppression of complement activation. It is not clear at present
whether the levels of expression of DAF and intrarenal C3 synthesis
correlate with the level of tissue injury.
Methods. Immunohistochemistry for DAF and C3 and nonradioactive in
situ hybridization with digoxigenin-labeled oligonucleotide probe for DAF
and C3 mRNA were performed in 22 tissue samples of kidneys from
patients with IgA nephropathy (IgAN), 6 with membranous nephropathy
(MN), 6 with lupus nephritis (LN), and five normal kidneys.
Results. In the normal kidney, DAF was confined to the juxtaglomerular
apparatus and little or no C3 was detected; however, a few glomerular cells
were positive for DAF mRNA but no C3 mRNA positive cells were
detected. In diseased kidneys, DAF and C3 as well as their mRNAs were
detected in mesangial cells, tubular cells and infiltrating cells. Glomerular
epithelial cells and Bowman’s capsule cells contained little or no DAF and
C3 but were positive for their mRNAs. The mean percentages of
mesangial cells positive for DAF and C3 mRNAs were 49.3 6 11.5% and
50.7 6 10.3% in IgAN, and 17.0 6 6.3% and 19.4 6 9.0% in MN,
respectively. The percentage of mesangial cells positive for DAF and C3
mRNAs among intraglomerular cells correlated positively with the degree
of mesangial proliferation and glomerular sclerosis in IgAN. In contrast, in
LN the percentage of glomerular cells positive for DAF mRNA correlated
negatively with the degree of glomerular injury, while the percentage of
cells positive for C3 mRNA did not change with the progression of the
disease. The ratio of C3 mRNA/DAF mRNA of glomerular cells corre-
lated with the degree of glomerular injury in both IgAN and LN. In the
tubulointerstitium, the percentage of cells expressing mRNA, and C3
mRNA/DAF mRNA ratio correlated with the degree of tubular atrophy
and interstitial broadening in both IgAN and LN.
Conclusions. We conclude that DAF and C3 mRNAs are synthesized in
human diseased kidneys, and that a balance between locally synthesized
DAF and C3 may be important in the progression of glomerulonephritis.
Immune complex-mediated glomerulonephritis is associ-
ated with complement activation. This is evident serologi-
cally by the presence of reduced levels of systemic comple-
ment components [1] and circulating complement
activation products [2], and histochemically by deposition
of complement components [3] and membrane attack
complex [4, 5] in the nephritic kidney.
Recent studies have shown that the site of synthesis of
complements is not limited to the liver [6]. Certain renal
cells such as glomerular mesangial cells [7, 8], epithelial
cells [9, 10] and tubular epithelial cells [11] also synthesize
C3 and/or C4 in vitro. This fact is further substantiated by
the demonstration of intraglomerular C3 synthesis in hu-
man immune-mediated glomerulonephritis by in situ hy-
bridization [12]. In addition, intrarenally synthesized com-
plement components may also be involved in the
inflammatory process affecting the kidney. Prior to assess-
ing the degree of participation of the intrarenally synthe-
sized complements, we first investigated whether the rate
and site of production of C3 in the kidney correlate with the
severity of renal injury in various forms of nephropathies.
By recognizing that for the intrarenally produced com-
plements to participate in the injury, the complements
should be activated in situ, we also investigated whether
complement regulatory proteins, particularly decay accel-
erating factor (DAF), are co-expressed at the site of
complement production to regulate the complement acti-
vation. DAF, a cell membrane-associated protein, acts on
the first step of the complement cascade by suppressing the
activation of C3 [13, 14] and regulating the activities of both
classic and alternative complement pathways.
Immunohistochemical studies by Cosio et al [15] dem-
onstrated the presence of DAF in glomeruli, interstitium
and blood vessels in the kidneys of patients with comple-
ment-mediated glomerulonephritis. Based on differences
in molecular and functional characteristics of urine and
serum DAF, these workers postulated that DAF may be
synthesized in the kidney by renal cells. This was later
supported in part by the results of a study reported by
Shibata, Cosio and Birmingham [16], who showed that
cultured human mesangial cells produced DAF mRNA and
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that the synthesis was increased by exposure of activated
complement components to human mesangial cells.
Our results showed the presence of DAF and C3 as well
as mRNA for DAF and C3 in diseased kidneys, and that
the C3 mRNA/DAF mRNA ratio correlated positively with
the degree of injury both in immunoglobulin A nephropa-
thy (IgAN) and lupus nephritis (LN). Based on our find-
ings, we speculate that the balance between locally synthe-




Kidney specimens were obtained from open renal biop-
sies of 34 patients with glomerular diseases. Of these, 22
had IgAN, 6 had membranous nephropathy (MN) without
cellular proliferation, and 6 had LN [2 cases with mesangial
proliferative lupus nephritis (mesLN) and 4 cases with
diffuse proliferative lupus nephritis (DPLN)]. Patients with
IgAN were divided into two groups: IgAN-I with a mini-
mal-to-mild lesions and IgAN-II with moderate-to-ad-
vanced lesions, according to the histopathological findings
described elsewhere [17]. All patients gave informed con-
sent to the open renal biopsy and the present study [18].
Diagnosis of renal disease was based on clinical, immuno-
fluorescence, light microscopic and electron microscopic
findings. No patient had been treated with steroids or
immunosuppressive drugs prior to renal biopsy. Five nor-
mal kidney portions were obtained by nephrectomy per-
formed for adenocarcinoma and served as a control. Sam-
ples were frozen in O.C.T. compound (Miles Inc., Elkhardt,
IN, USA) and stored at 280°C until use.
The following clinical parameters were examined at the
time of open renal biopsy: age, gender and the level of
serum creatinine, urinary protein and hematuria. The
severity of hematuria was graded as follows: 0 5 0 to 5
erythrocytes per high-power field; 1 5 5 to 30 erythrocytes
per high-power field; 2 5 .30 erythrocytes per high-power
field; and grade 3 5 when hematuria was macroscopic.
These parameters are summarized in Table 1.
Oligonucleotides and labeling
Sense and antisense oligonucleotides for human C3
mRNA corresponded to bases no. 944-968 of human C3
cDNA, as described previously [12]. The probe for DAF
mRNA corresponded to sequences no. 164-193 of the
cDNA [19, 20]. The sequences used in this study had no
significant homology with any other known sequences
deposited in the latest release of the GenBank data (Gen-
Bank, Release 85, December 1996). The oligonucleotide
was synthesized on an automated DNA synthesizer (Model
391; PCR-MATE EP, Foster City, CA, USA) and was
labeled using a digoxigenin (DIG) oligonucleotide tailing
kit according to the protocol provided by the manufacturer
(Boehringer Mannheim Biochemica, Mannheim, Germany).
In situ hybridization
In situ hybridization was performed using a slightly
modified technique originally developed in our laboratory
[21]. Specimens were cut to a thickness of 4 mm and placed
on glass slides coated with 3-aminopropyltriethoxysilane
(A3684; Sigma, St. Louis, MO, USA). The sections were
fixed with 4% paraformaldehyde in phosphate-buffered
saline and then deproteinized using HCl and proteinase K
(Sigma P-4914). After prehybridization, sections were hy-
bridized with DIG-labeled oligonucleotide probe in the
prehybridization buffer. After washing with 0.075% BRIJ
(Sigma 430 AG-6) in 23 and 0.53 standard saline citrate at
room temperature, the sections were stained immunohis-
tochemically to visualize the hybridized DIG-labeled probe
using mouse monoclonal anti-DIG antibody (Boehringer
Mannheim Biochemica 1333 062), horseradish peroxidase
(HRP)-conjugated rabbit anti-mouse antibody (Dako P260;
Dakopatts, Glostrup, Denmark) and HRP-conjugated
Table 1. Clinical parameters for the patients in this study









1 F 21 IgA nephropathy I 0.6 0.7 3
2 M 21 IgA nephropathy I 0.9 1.4 3
3 M 47 IgA nephropathy I 1.0 0.7 2
4 F 24 IgA nephropathy I 0.7 0.1 3
5 M 23 IgA nephropathy I 1.0 1.2 3
6 F 46 IgA nephropathy I 0.9 0.2 2
7 F 21 IgA nephropathy I 0.6 0.1 3
8 F 44 IgA nephropathy I 0.9 0.7 3
9 F 39 IgA nephropathy I 1.0 0.2 0
10 F 39 IgA nephropathy I 0.6 0.2 3
11 M 35 IgA nephropathy I 1.0 1.2 3
12 M 56 IgA nephropathy II 1.5 0.4 2
13 M 51 IgA nephropathy II 1.5 5.3 2
14 M 44 IgA nephropathy II 1.5 0.9 3
15 F 20 IgA nephropathy II 0.6 0.4 3
16 F 44 IgA nephropathy II 3.3 8.1 3
17 F 42 IgA nephropathy II 1.0 0.4 3
18 M 46 IgA nephropathy II 2.0 1.3 3
19 M 44 IgA nephropathy II 1.5 0.5 3
20 M 35 IgA nephropathy II 1.5 0.3 3
21 M 45 IgA nephropathy II 1.7 0.8 2
22 F 28 IgA nephropathy II 0.8 0.6 3
23 M 52 Membranous nephropathy aS1 0.9 2.2 1
24 F 60 Membranous nephropathy aS1 0.9 1.1 2
25 M 20 Membranous nephropathy aS1 0.9 0.5 1
26 M 63 Membranous nephropathy aS1 0.9 1.4 1
27 M 46 Membranous nephropathy aS1 0.9 1.5 1
28 M 54 Membranous nephropathy aS1 0.8 2.5 1
29 F 48 Lupus nephritis b4/3 0.8 1.5 0
30 F 33 Lupus nephritis b3/3 0.5 1.5 3
31 F 41 Lupus nephritis b3/9 1.6 6.5 3
32 M 20 Lupus nephritis b3/5 0.9 0.3 0
33 F 21 Lupus nephritis b0/7 0.9 3.5 3
34 M 38 Lupus nephritis b8/9 2.7 3.0 3
a S staging of membranous nephropathy
b Chronicity Index/Activity Index in lupus nephritis
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swine anti-rabbit antibody (Dako P399) successively. Color
was developed by reaction with H2O2 and diaminobenzi-
dine tetrahydrochloride. Finally, the sections were counter-
stained with methyl green and mounted. To define the type
of positive cells in relation to glomerular basement and
mesangial areas, the sections were stained with PAS (peri-
odic acid-Schiff reaction) after in situ hybridization as
described previously [12]. Two or more observers who were
unaware of the clinical and laboratory findings indepen-
dently examined each section and evaluated the expression
of DAF mRNA and C3 mRNA in the glomeruli and
tubulointerstitium. In this study, five to seven glomeruli per
tissue section were analyzed. Changes in glomeruli were
graded semi-quantitatively using a scale of 1 to 4 according
to the categories of histological changes described by
Niemir et al [22] with some modifications: 1 5 minimal
glomerular abnormalities; 2 5 diffuse mild-to-moderate
mesangial proliferation; 3 5 mesangial proliferation with
segmental crescents; 4 5 pronounced glomerular sclerosis
(global or segmental). After determining the degree of
glomerular injury, we counted the number of mesangial
cells and glomerular epithelial cells positive for DAF
mRNA or C3 mRNA and total intraglomerular cells in the
same glomeruli in IgAN, MN and mesLN. Using these
counts, we calculated the percentages of mesangial cells
positive for DAF mRNA (m%D) or C3 (m%C), as well as
epithelial cells positive for DAF mRNA (e%D) or C3
(e%C) among intraglomerular cells. In DPLN, we counted
the total number of glomerular cells positive for the
mRNAs because the extensive cellular proliferation makes
it very hard to distinguish the different types of glomerular
cells. In LN (mesLN plus DPLN), we calculated the
percentage of glomerular cells positive for DAF mRNA
(g%D) or C3 (g%C) among intraglomerular cells.
Cells clearly stained in the cytoplasm or stained with a
perinuclear pattern were identified as DAF mRNA and C3
mRNA positive cells. On the other hand, cells with nuclei
stained with methylgreen alone were considered negative
for DAF mRNA and C3 mRNA.
In the tubulointerstitium, we examined five to seven
fields of the cortical interstitium in each section under a low
magnification (3100), and analyzed three representative
interstitial fields, as previously described [23]. In each
designated field, following determination of the degree of
tubular atrophy and interstitial broadening, we calculated
the proportion of tubules positive for the mRNAs relative
to the total number of tubules (t%D and t%C). We also
calculated the proportion of interstitial cells positive for the
mRNAs among total infiltrating cells (i%D and i%C). In
each field, tubulointerstitial changes, including tubular
atrophy, dilation and interstitial broadening were graded
semiquantitatively using a scale of 1 to 4 (absent or
minimal, mild, moderate, and marked) according to the
method of Pirani et al [24]. In order to discern the balance
between the expression of C3 mRNA and DAF mRNA in
IgAN and LN, we calculated the ratio between the percent-
age of C3 mRNA-positive cells and percentage of DAF
mRNA-positive cells per glomerulus and interstitial field
(C/D). In the glomerulus, m%C/m%D, e%C/e%D repre-
sented C/D ratio in mesangial cells and glomerular epithe-
lial cells in IgAN, respectively, while g%C/g%D was the
C/D ratio in total glomerular cells in LN. In the tubuloint-
erstitium, t%C/t%D and i%C/i%D represented the C/D
ratio in tubules and infiltrating cells in IgAN and LN,
respectively.
To evaluate the specificity of the signals for DAF mRNA
and C3 mRNA, we performed three control experiments
including pre-treatment of RNase, a study with a sense
probe and a competitive study, as described previously [21].
These control experiments confirmed the specificity of
DAF mRNA and C3 mRNA as previously described [12, 21].
Immunohistochemistry
Sections from frozen kidney tissues were reacted with
monoclonal antibodies against DAF (Wako, Osaka, Japan)
or C3 (Dako M836) and stained with HRP-conjugated
rabbit anti-mouse immunoglobulin and HRP-conjugated
swine anti-rabbit immunoglobulin, as described in the
procedure of in situ hybridization. To identify infiltrating
cells among those stained positive for DAF and C3 mR-
NAs, serial fresh frozen sections were reacted with mono-
clonal antibodies against CD68 (Dako M718) and CD3
(Becton-Dickinson 347340; Bectin-Dickinson, San Jose,
CA, USA), representing surface markers of monocytes and
Fig. 1. Immunohistochemistry for decay
accelerating factor (DAF) protein (a) and in
situ hybridization study for DAF mRNA in
renal sections of control kidney (b)
(magnification, 3200). (a) DAF is present only
in juxtaglomerular apparatus. (b) Most nuclei
are stained by methyl green in cells negative for
DAF mRNA.
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T lymphocytes, respectively. Mouse IgG1 was used as a
negative control (Dako X931) instead of monoclonal anti-
bodies. The numbers of immunoreactive cells in renal
tissues were scored separately in glomeruli and interstitium
according to the following scheme as previously described
[22]: 1 5 single positive cells in a focal distribution; 2 5
diffusely scattered positive cells; 3 5 numerous positive
cells, frequently in clusters.
Statistical analysis
Differences between groups were analyzed using one-
way repeated measures ANOVA using the Bonferroni
method. Correlations between two variables were tested for
significance using the Spearman’s rank and Pearson’s cor-
relation tests. A P value less than 0.05 was considered
statistically significant.
RESULTS
Expression of DAF and DAF mRNA
Normal kidney: Glomeruli. No cell was positive for DAF
(Fig. 1a), but a few glomerular cells were positive for DAF
mRNA (Fig. 1b).
Fig. 2. Immunohistochemistry for decay
accelerating factor (DAF) protein in glomeruli
of patients with immunoglobulin A
nephropathy (IgAN; a) and in situ hybridization
study for DAF mRNA in patients with IgAN (b,
mild lesion; c, severe lesion), membranous
nephropathy (MN; d) and lupus nephropathy
(LN; e) (magnification, 3200). In situ
hybridization followed by PAS staining in IgAN
(f and g) and LN (h) (magnification for f, g, and
h, 3400). Cells positive for DAF mRNA in
glomeruli (b, d, arrowheads). Note the
expression of DAF mRNA in mesangial cells
within the PAS positive mesangial matrix
(f, arrows), cells of Bowman’s capsule
(f, arrowheads), glomerular epithelial cells
(g, arrows), and glomerular endothelial cells
(h, arrow).
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Normal kidney: Interstitium. DAF was present only in the
juxtaglomerular apparatus (JGA) (Fig. 1a). DAF mRNA
was found in few tubulointerstitial cells, but not in JGA
(Fig. 1b).
Diseased kidney: Glomeruli. Mainly mesangial cells were
positive for DAF protein in IgAN (Fig. 2a), MN and LN. A
large number of cells were positive for DAF mRNA in
biopsy specimens of IgAN, MN and LN (Fig. 2 b-e). After
PAS staining, DAF mRNA positive cells were identified as
mesangial cells within the PAS-positive mesangial matrix,
epithelial cells on the capillary basement membrane and
some cells of the Bowman’s capsule (Fig. 2 f, g). In
addition, some endothelial cells stained for DAF mRNA in
LN (Fig. 2h) and endothelial cells in IgAN and MN
occasionally contained DAF mRNA. When a section adja-
cent to that stained for DAF mRNA was stained immuno-
histochemically for CD68 or CD3, the number of intraglo-
merular cells positive for DAF mRNA was greater than
that of CD68 (Fig. 3) or CD3 (data not shown) positive
mononuclear cells.
Diseased kidney: Interstitium. In the interstitium of the
diseased kidney, some proximal tubular epithelial cells and
infiltrating cells (Fig. 4a) were positive for DAF. DAF
mRNA positive cells were observed in some tubular epi-
thelial cells (Fig. 4b). The signal was markedly high in the
cells of atrophic tubules in IgAN (Fig. 4c), MN and LN. In
areas with moderate-to-severe interstitial lesions, some
infiltrating cells (Fig. 4d) were positive for DAF mRNA.
With regard to the expression of DAF mRNA in blood
vessel, vascular smooth muscle cells or myointimal cells
(Fig. 4e) and vascular endothelial cells (Fig. 4f) in inter-
lobular arteries were also positive for DAF mRNA.
Expression of C3 and C3 mRNA
Normal kidney. Immunoreactive C3 and C3 mRNA were
not observed in the control tissue (Fig. 5).
Diseased kidney: Glomeruli. In the diseased kidney, C3
was present mainly in the mesangial area and in occasional
epithelial cells and some cells of the Bowman’s capsule. C3
mRNA was present in mesangial cells, glomerular epithe-
lial cells and a number of cells of the Bowman’s capsule
(Fig. 6).
Diseased kidney: Interstitium. C3 and C3 mRNA were
detected in some tubular epithelial cells and infiltrating
cells as previously reported [12].
Percentage of cells expressing DAF mRNA or C3 mRNA
in glomeruli
The mean percentages of mesangial cells positive for
DAF mRNA (m%D) and C3 mRNA (m%C) among total
glomerular cells were significantly higher in glomeruli of
patients with IgAN than in MN and mesLN (Fig. 7A).
Furthermore, the percentage of cells was higher in glomer-
uli of patients with IgAN-II than in IgAN-I (Fig. 7A). In
contrast, the mean percentages of glomerular epithelial
cells positive for DAF mRNA (e%D) or C3 mRNA (e%C)
among total glomerular cells were significantly higher in
glomeruli of patients with MN than in IgAN and mesLN
(Fig. 7B).
Relationship between m%D or m%C in individual
glomerulus and histopathological scale
Since the degree of glomerular injury is heterogeneous
during the progression of glomerulonephritis [25], expres-
sion of DAF mRNA or C3 mRNA in each glomerulus
correlates with the degree of injury of each glomerulus
rather than the average severity of the injury in each
section, as previously described [26]. There was a positive
correlation between m%D or m%C in individual glomer-
ulus of patients with IgAN and its histopathological scale
(Fig. 8 and Table 2). Since the regression coefficient for
m%C was higher than that of m%D, m%C/m%D corre-
lated significantly with the histopathological scale (Fig. 9
and Table 2). e%D or e%C was similar regardless of the
histopathological scale (Fig. 8 and Table 2), and, therefore,
e%C/e%D also did not correlate with the histopathological
scale in IgAN (Fig. 9 and Table 2). In the individual
glomerulus of patients with LN, g%D correlated negatively
with the histopathological scale and g%C was similar
regardless of the histopathological scale (Fig. 8 and Table
2). Consequently, g%C/g%D correlated positively with the
histopathological scale in LN (Fig. 9 and Table 2). Exam-
ination of the expression of mRNAs and histological scale
Fig. 3. In situ hybridization for decay
accelerating factor (DAF) mRNA and
immunohistochemistry for CD68 as a marker
of monocytes on serial sections of IgAN
(magnification, 3200). (a) Note cells positive
for DAF mRNA in the glomerulus
(arrowheads). (b) An adjacent section to panel
a. Monocytes are only present around the
glomerulus (arrowheads).
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per glomerulus in each patient showed a similar variability
in both parameters (data not shown).
Relationship between expression of DAF mRNA or C3
mRNA in tubulointerstitium and histopathological scale
The mean percentage of tubules positive for DAF
mRNA (t%D) and C3 mRNA (t%C) among total number
of tubules correlated positively with the degree of tubular
atrophy in IgAN (Fig. 10 and Table 3) and LN (Table 3).
The mean percentages of infiltrating cells positive for DAF
mRNA (i%D) and C3 mRNA (i%C) among total infiltrat-
ing cells were also higher in broader interstitium in IgAN
(Fig. 10 and Table 3) and LN (Table 3). The ratios
t%C/t%D and i%C/i%D correlated positively with the
Fig. 4. Immunohistochemistry for decay
accelerating factor (DAF) protein in the
interstitium of lupus nephritis (LN; a)
(magnification, 3 200) and in situ detection of
DAF mRNA in the interstitium of IgAN (b, c, d,
e, and f) (magnification, 3200). (b) Proximal
tubular epithelial cells positive for DAF
mRNA. (c) DAF mRNA is strongly expressed
in epithelial cells of atrophic tubules (arrows).
(d) Some infiltrating cells positively stained for
DAF mRNA. (e, f) DAF mRNA is expressed
by myointimal cells in intimal fibroplasia or
vascular smooth muscle cells (e; arrows) and
vascular endothelial cells (f; arrowheads) of
interlobular artery.
Fig. 5. Immunohistochemistry for C3 protein
(a) and in situ hybridization study for C3
mRNA (b) in sections of control kidney
(magnification, 3200).
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scale of tubulointerstitial injury in both types of glomeru-
lonephritis (Fig. 10 and Table 3).
Relationship between expression of DAF or C3 protein
and histopathological scale
In glomeruli and tubulointerstitium, the expression of
DAF or C3 protein did not correlate with the degree of
tissue injury.
Relationship between expression of DAF or C3 and
clinical parameters
We also examined the relationship between mRNAs
expression and clinical parameters in patients with IgAN
and LN, and found that m%C/m%D in IgAN and t%C and
t%D in IgAN and LN correlated with the level of protein-
uria (P , 0.01). In both IgAN and LN, the i%C, t%C,
Fig. 6. In situ detection of C3 mRNA in tissue
sections from patients with IgAN (a, b), MN
(c), and LN (d). Note the presence of cells
positive for C3 mRNA in the glomeruli (a, c,
arrowheads) (magnification, 3200).
Fig. 7. Pattern of expression of DAF
mRNA and C3 mRNA in the glomeruli.
The total number of intraglomerular cells,
mesangial cells and glomerular epithelial
cells positive for DAF and C3 mRNAs
were counted under a microscope, and the
proportion of mesangial cells (A) and
glomerular epithelial cells (B) positive for
each mRNA among intraglomerular cells
was calculated. Differences between groups
were examined using one way ANOVA
with the Bonferroni method (*P , 0.05).
(A) In renal tissue from patients with
IgAN, the ratio of mesangial cells is
significantly higher than that of MN and
mesLN. In IgA-II, the ratio is significantly
higher than in IgAN-I. (B) In contrast,
glomerular epithelial cells positive for both
mRNAs are significantly higher in patients
with MN than in IgAN and mesLN.
Symbols are: (n) IgA-I; (o) IgA-II; (1)
MN; (^) mesLN.
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i%C/i%D and t%C/t%D correlated with the level of serum
creatinine (P , 0.01, 0.05, 0.05 and 0.01, respectively).
However, there was no relationship between the expression
of DAF or C3 protein and any clinical parameters.
DISCUSSION
The major findings of the present study were: (a) DAF
and C3 were localized in diseased human kidneys, and (b)
identification of the cell type that synthesize DAF mRNA
and C3 mRNA. To our knowledge, this is the first descrip-
tion of the presence of DAF mRNA in the diseased kidney.
(c) We also showed that the sites expressing DAF mRNA
and C3 mRNA and the level of expression of these mRNA
varied with the progression of renal tissue injury in differ-
ent types of glomerulonephritis.
Since DAF is expressed on the surface of most circulat-
ing cells [27–29], the contribution of infiltrating cells to
DAF mRNA positive cell pool in the glomeruli was as-
sessed by identifying CD68 (a marker of monocytes) and
CD3 (a marker of lymphocytes) positive infiltrating cells
among the DAF mRNA positive intraglomerular cells. Our
results indicated that most of the cells positive for DAF
mRNA were glomerular resident cells, and that the contri-
bution of infiltrating cells to the focal concentration of
DAF was very small or negligible. Furthermore, the pres-
ence of DAF mRNA in a variety of glomerular cells implies
that most cells in glomeruli are capable of producing DAF.
The present study demonstrated that glomerular distri-
bution of DAF mRNA and C3 mRNA-positive cells are
different among three types of glomerulonephritis, reflect-
ing differences in the primary site of renal damage. In
IgAN, where IgA and C3 protein are mainly deposited in
the mesangium [30], mesangial cells are considered as the
principal site of glomerular injury. Most of DAF mRNA
and C3 mRNA were found in these cells, and, in fact, the
percentages of mesangial cells containing DAF mRNA and
C3 mRNA correlated with the degree of glomerular injury
in IgAN. In MN, glomerular epithelial cells are considered
as the main site of injury and these cells predominantly
expressed DAF mRNA and C3 mRNA. In LN, DNA-anti-
DNA IgG immune complexes are deposited at various
locations, such as the subendothelium, glomerular base-
ment membrane, subepithelium and mesangial area [31,
32] and those cells were positive for DAF mRNA and C3
mRNA. In particular, our results demonstrating that the
expression pattern of DAF and C3 mRNAs in mesLN dif-
fered from that in IgAN indicate that different pathogenic
mechanisms may determine the site producing complement
and its inhibitor. This colocalization of the primary sites of
Fig. 8. Correlation between the expression of DAF mRNA or C3 mRNA and the degree of glomerular injury in IgAN (A) and LN (B), analyzed using
Spearman’s rank correlation test. The scale used to define the degree of glomerular injury is explained in Methods. (A-I) In IgAN, the percentage of
mesangial cells positive for DAF mRNA (m%D) and C3 mRNA (m%C) correlated positively with the degree of glomerular injury (P , 0.01). (A-II)
In contrast, the percentage of epithelial cells positive for DAF mRNA (e%D) or C3 mRNA (e%C) did not change with the progression of the disease.
(II) In LN, the percentage of glomerular cells positive for DAF mRNA (g%D) correlated negatively with the degree of glomerular injury (P , 0.01),
whereas the percentage of glomerular cells positive for C3 mRNA (g%C) did not change with the progression of the disease.
Table 2. Correlation between the proportion of DAF and C3 mRNA
positive cells and the degree of glomerular injury in IgAN and LN
r P
IgAN
m%D 0.321 , 0.01
m%C 0.490 , 0.01
e%D 20.126 NS
e%C 0.041 NS
m%C/m%D 0.352 , 0.01
e%C/e%D 0.241 NS
LN
g%D 20.799 , 0.01
g%C 0.094 NS
g%C/g%D 0.685 , 0.001
Abbreviations are: m%D, percentage of mesangial cells positive for
DAF mRNA; m%C, percentage of mesangial cells positive for C3 mRNA;
e%D, percentage of epithelial cells positive for DAF mRNA; e%C,
percentage of epithelial cells positive for C3 mRNA; C/D, the ratio
between the percentage of C3 mRNA-positive cells and percentage of
DAF mRNA-positive cells per glomerulus; m%C/m%D; C/D ratio in
mesangial cells; e%C/e%D, C/D ratio in glomerular epithelial cells; g%D,
percentage of glomerular cells positive for DAF mRNA; g%C, percentage
of glomerular cells positive for C3 mRNA; g%C/g%D, C/D ratio in total
glomerular cells.
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renal injury and DAF mRNA and/or C3 mRNA-positive
cells in glomeruli suggests that there is a local cause and
effect relationship between the site of injury and produc-
tion of DAF and C3. However, the number of patients in
our study was too small to make a firm conclusion regard-
ing site-specific synthesis of DAF and C3 in glomeruli of a
variety of renal diseases.
In contrast to the different glomerular expressions of
DAF and C3 mRNAs between IgAN and LN, we demon-
strated that the glomerular C/D ratio correlated with the
severity of glomerular injury in both IgAN and LN. These
results suggest that the balance between cells expressing C3
mRNA and those expressing DAF mRNA tilted in favor of
the cells expressing C3 mRNA as the state of glomeruli
deteriorated. These findings suggest that complement acti-
vation overcome complement inhibition by DAF, leading
to the progression of renal injury. In this regard, several
reports have indicated the importance of balance between
activated C3 and inhibitor of activated C3 in experimental
renal injury models. Matsuo and colleagues [33–35] have
demonstrated that treatment with 5I2Ab, an antibody
against a membrane inhibitor of C3, homologous to human
DAF and membrane cofactor protein, increased the depo-
sition of C3 and enhanced glomerular and tubulointerstitial
injury in a rat model of glomerulonephritis. Furthermore,
transgenic animals expressing complement regulatory pro-
teins, such as DAF and membrane cofactor protein, are
resistant to complement attack in xenotransplantation [36–
38]. Provided that the balance dictates the clinical state, it
may be suggested that a certain focal concentration of
activated C3 may be tolerated when sufficient DAF is in the
area to inactivate the activated C3, but when the concen-
tration of activated C3 exceeds the level of tolerance,
progression of injury predominates in the net pathological
process.
Since in injured glomeruli, DAF mRNA and C3 mRNA
are co-expressed in a given cell and DAF is an inhibitor of
activated C3, complement-mediated cell injury may be
limited to the level of glomerular cells. The mechanism of
DAF synthesis remains to be elucidated, however, several
in vitro experiments have examined such mechanisms. The
finding that mesangial cells produced DAF when the cells
were exposed to membrane attack complexes (C5b-C9) in
vitro [16] suggests a direct involvement of complement
components in DAF synthesis. In support of an indirect
involvement, certain cytokines such as IL-4 and IFN-g,
Fig. 9. Correlation between the ratio of
percentage of C3 mRNA-positive cells to the
percentage of DAF mRNA-positive cells per
glomerulus (C/D) and glomerular injury in
IgAN (A) and LN (B). The scale used to define
the degree of glomerular injury is explained in
the Methods section. (A) In IgAN, C/D ratio in
mesangial cells (m%C/m%D, F) correlated
positively with the histopathological scale (P ,
0.01), whereas the C/D ratio in glomerular
epithelial cells (e%C/e%D, E) did not change
with the progression of the disease. (B) In LN,
C/D ratio (g%C/g%D, F) correlated positively
with the histopathological scale (P , 0.001).
Fig. 10. Correlation between the expression of DAF mRNA or C3 mRNA and the degree of tubulointerstitial injury in IgAN, analyzed using
Spearman’s rank correlation test. The scale used to define the degree of tubular atrophy is explained in the Methods section. (A) The proportion of
tubules positive for the mRNAs relative to the total number of tubules in DAF mRNA (t%D) and C3 mRNA (t%C) correlated positively with the
degree of tubular atrophy (t%D, E; P , 0.05, t%C, F; P , 0.01). (B) The proportion of infiltrating cells positive for DAF mRNA (i%D, E) and C3
mRNA (i%C, F) also correlated with the scale of interstitial broadening (P , 0.01). (C) When the ratio between the percentage of C3 mRNA-positive
tubules and percentage of DAF mRNA-positive tubules per interstitial field (C/D) was calculated in tubules (t%C/t%D, F) and infiltrating cells
(i%C/i%D, E), both correlated positively with the scale of tubulointerstitial injury (P , 0.05).
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produced in glomerulonephritis [23, 39], stimulate the
synthesis of DAF in variety of cells [40, 41]. If the synthesis
of DAF is activated by an agent, this may serve as a new
therapeutic strategy for complement-dependent glomeru-
lonephritis. In any case, further studies are necessary to
elucidate the mechanisms that control DAF synthesis in
kidney cells.
The present study also showed tubular expression of
DAF mRNA, indicating that tubular cells have the capacity
of producing DAF in addition to C3. Although the mech-
anism of synthesis of DAF in the tubules is not fully
understood, certain cytokines, like IL-2 and IFN-g, may
stimulate tubular epithelial cells to induce the production
of complement components [11, 42], while C3 activation
occurs spontaneously by high concentrations of ammonia in
tubulointerstitium [43]. Thus, an increase of activated C3
production may in turn induce DAF expression in the
corresponding tubules and infiltrating cells to protect
against a complement attack. Interestingly, the C/D ratio in
the tubulointerstitium, as in the glomeruli, correlated pos-
itively in IgAN and LN with the degree of tubulointerstitial
changes. This finding indicates that a balance between
complement activation and its inhibition is also important
for the progression of interstitial tissue injury.
In conclusion, we have shown that DAF and C3 mRNAs
are expressed in mesangial cells, glomerular epithelial cells
and cells of Bowman’s capsule in diseased kidneys. The
expression of DAF and C3 in glomeruli may be induced in
a site-specific manner in different types of glomerulone-
phritis. In the tubulointerstitium, some tubular epithelial
and infiltrating cells also synthesize DAF and C3 mRNAs
and increased levels of both mRNAs may induce tubuloin-
terstitial injury through a common pathway in different
type of nephritis. Finally, our studies suggest that a balance
between in situ synthesis of DAF and C3 is critical for the
progression of renal injury in various forms of glomerulo-
nephritis.
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APPENDIX
Abbreviations used in this article are: C/D, the ratio between the
percentage of complement C3 mRNA-positive cells and percentage of
DAF mRNA-positive cells per glomerulus and interstitial field; DAF,
decay accelerating factor; DIG, digoxigenin; DPLN, diffuse proliferative
lupus nephritis; e%C, percentage of epithelial cells positive for C3 mRNA
among intraglomerular cells; e%C/e%D, C/D in epithelial cells; e%D,
percentage of epithelial cells positive for DAF mRNA among intraglo-
merular cells; g%C, percentage of glomerular cells positive for C3 mRNA
among intraglomerular cells; g%C/g%D, C/D in glomerular cells; g%D,
percentage of glomerular cells positive for DAF mRNA among intraglo-
merular cells; HRP, horseradish peroxidase; i%C, percentage of infiltrat-
ing cells positive for C3 mRNA among total infiltrating cells; i%C/i%D,
C/D in infiltrating cells; i%D, percentage of infiltrating cells positive for
DAF mRNA among total infiltrating cells; IgA, immunoglobulin A; IgAN,
IgA nephropathy; IgAN-I, IgAN with minimal-to-mild lesions; IgAN-II,
IgAN with moderate-to-advanced lesions; JGA, juxtaglomerular appara-
tus; LN, lupus nephritis; mesLN, mesangial proliferative lupus nephritis;
m%C, percentage of mesangial cells positive for C3 mRNA among
intraglomerular cells; m%C/m%D, C/D in mesangial cells; m%D, per-
centage of mesangial cells positive for DAF mRNA among intraglomeru-
lar cells; MN, membranous nephropathy; t%C, percentage of tubules
positive for C3 mRNA among total number of tubules; t%C/t%D, C/D
ratio in tubules; t%D, percentage of tubules positive for DAF mRNA
among total number of tubules.
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